9 results about "Allergic response" patented technology

The present invention relates to tetrahydrobenzo-isoquinoline sulfonamides derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the FIERI receptor.

Tree pollen allergy is seasonal allergy caused by various tree pollen spread in air. The allergy affects a substantial proportion of populations, is particularly significant in European and North America areas, and is characterized by symptoms such as sneezing, nasal obstruction, rhinorrhea, eye itching and lacrimation, and throat irritation. The symptoms typically occur in spring, at which birch, alder, hazel and oak release pollen into the air. Tree pollen allergy is a type 1 hypersensitivity reaction mediated by an immunoglobulin E (IgE) antibody. The present invention relates to antibodies and antigen binding fragments thereof that bind to one or more of tree pollen allergens Bet v 1, Aln g 1, Cor a 1 and Quue a 1, resulting in inhibition of IgE-mediated anaphylaxis.

The present invention provides systems and methods for predicting an allergic response in a subject by measuring the amounts of RNA species from B cells that encode at least a part of the Immunoglobulin E (IgE) constant region (Cε), such as nonproductive epsilon germline transcripts (εGLTs).

Tree pollen allergy is a seasonal allergy caused by various tree pollens suspended in the air. This allergy affects a significant proportion of the population, particularly in Europe and North America, and is characterized by symptoms such as sneezing, nasal congestion, runny nose, itchy or watery eyes, and throat inflammation. These symptoms typically occur in spring when trees such as birch, alder, hazel, and oak release pollen into the air. Tree pollen allergy is a type 1 hypersensitivity reaction mediated by immunoglobulin E (IgE) antibodies. This invention relates to antibodies and their antigen-binding fragments that bind to one or more tree pollen allergens, Bet v 1, Aln g 1, Cor a 1, and Que a 1, and inhibit the IgE-mediated allergic reaction.

The present disclosure relates to the use of IgE for identifying individuals with genetic defects that lead to the expression of protein truncations, extended proteins, to a loss of protein expression or to the expression of mutated proteins. The method is based on a skin prick test, wherein IgE that is specific for the protein of interest is administered onto the skin. If the protein or protein variant that is specifically identified by IgE is present in the skin, the IgE, which was allowed to enter the skin by the skin prick, binds the target protein and then the protein-bound IgE triggers mast cells and / or basophiles in the skin to release granules, resulting in the development of a transient allergic reaction.

The invention discloses an anti-nasal allergy gel production optimization method based on data analysis, particularly relates to the field of resource allocation and production optimization, and is used for solving the problems that in the existing anti-allergic gel production process, response to regional and seasonal demand changes is delayed, and raw material supply constraint and production line switching cost are difficult to collaboratively balance. According to the method, raw material supply chain data, market sales records and environmental allergen time sequence data are collected to construct a unified space-time associated data basis, the recurrent neural network is utilized to predict the anti-allergic response intensity in a future production cycle, and product dosage form preference weights are formed based on association rule mining. On the basis, various executable candidate production schemes are generated in combination with raw material inventory and delivery cycle constraints, and decision selection is further performed on the schemes according to the real-time state of a production line and switching cost, so that refined configuration and efficient execution of the production process of the anti-nasal allergy gel are realized.

The present invention relates to dihydrocyclopenta-isoquinoline-sulfonamide derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the FcεRI receptor.

The disclosure provides for covalent dual-functional inhibitors of peanut allergic reactions where the inhibitors include a targeting moiety comprising a peanut allergen protein epitope or mimotope peptide sequence, a reactive functional group capable of forming a site-directed covalent bond to the amine moiety of a lysine amino acid of an allergen reactive immunoglobulin, and a variable length spacer comprising oligomers of ethylene glycol monomers, amino acids, saccharides, hydrocarbons, fluorinated hydrocarbons, or a combination thereof, wherein the 10 spacer is conjugated by one or more amide bonds to the TM and the FG.